This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2008 Sep-Oct;95(1-2):114-5.

doi: 10.1016/j.ymgme.2008.07.002. Epub 2008 Aug 12.

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta

Atul Mehta, Michael Beck, Christoph Kampmann, Andrea Frustaci, Dominique P Germain, Gregory M Pastores, Gere Sunder-Plassmann

PMID: 18701330
DOI: 10.1016/j.ymgme.2008.07.002

Comparative Study

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta

Atul Mehta et al. Mol Genet Metab. 2008 Sep-Oct.

. 2008 Sep-Oct;95(1-2):114-5.

doi: 10.1016/j.ymgme.2008.07.002. Epub 2008 Aug 12.

Authors

Atul Mehta, Michael Beck, Christoph Kampmann, Andrea Frustaci, Dominique P Germain, Gregory M Pastores, Gere Sunder-Plassmann

PMID: 18701330
DOI: 10.1016/j.ymgme.2008.07.002

No abstract available

PubMed Disclaimer

Comment in

Enzyme replacement therapy in Fabry disease: towards a better understanding of the implications of antibody formation and dose.
Hollak CE, Vedder AC, Winchester B, Aerts JM, Breunig F. Hollak CE, et al. Mol Genet Metab. 2008 Dec;95(4):239-40. doi: 10.1016/j.ymgme.2008.08.006. Epub 2008 Oct 7. Mol Genet Metab. 2008. PMID: 18842432 No abstract available.

Comment on

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.
Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B, Ten Berge IJ, Groener JE, Aerts JM, Wanner C, Hollak CE. Vedder AC, et al. Mol Genet Metab. 2008 Jul;94(3):319-25. doi: 10.1016/j.ymgme.2008.03.003. Epub 2008 Apr 18. Mol Genet Metab. 2008. PMID: 18424138 Clinical Trial.

Similar articles

Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM. Politei JM. J Obstet Gynaecol Res. 2010 Apr;36(2):428-9. doi: 10.1111/j.1447-0756.2009.01164.x. J Obstet Gynaecol Res. 2010. PMID: 20492401
Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
Senocak Tasci E, Bicik Z. Senocak Tasci E, et al. Iran J Kidney Dis. 2015 Sep;9(5):406-8. Iran J Kidney Dis. 2015. PMID: 26338166
Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
Kalkum G, Macchiella D, Reinke J, Kölbl H, Beck M. Kalkum G, et al. Eur J Obstet Gynecol Reprod Biol. 2009 May;144(1):92-3. doi: 10.1016/j.ejogrb.2009.01.007. Epub 2009 Feb 23. Eur J Obstet Gynecol Reprod Biol. 2009. PMID: 19233535 No abstract available.
Agalsidase alfa: specific treatment for Fabry disease.
Mehta A. Mehta A. Hosp Med. 2002 Jun;63(6):347-50. doi: 10.12968/hosp.2002.63.6.2005. Hosp Med. 2002. PMID: 12096664 Review.
The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF, Clarke JT. Morel CF, et al. Expert Opin Biol Ther. 2009 May;9(5):631-9. doi: 10.1517/14712590902902296. Expert Opin Biol Ther. 2009. PMID: 19368525 Review.

See all similar articles

Cited by

Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Hsu J, Serrano D, Bhowmick T, Kumar K, Shen Y, Kuo YC, Garnacho C, Muro S. Hsu J, et al. J Control Release. 2011 Feb 10;149(3):323-31. doi: 10.1016/j.jconrel.2010.10.031. Epub 2010 Nov 1. J Control Release. 2011. PMID: 21047542 Free PMC article.
Fabry disease.
Germain DP. Germain DP. Orphanet J Rare Dis. 2010 Nov 22;5:30. doi: 10.1186/1750-1172-5-30. Orphanet J Rare Dis. 2010. PMID: 21092187 Free PMC article. Review.
Fabry disease in children and the effects of enzyme replacement treatment.
Pintos-Morell G, Beck M. Pintos-Morell G, et al. Eur J Pediatr. 2009 Nov;168(11):1355-63. doi: 10.1007/s00431-009-0937-9. Epub 2009 Feb 26. Eur J Pediatr. 2009. PMID: 19242721 Free PMC article.
Medical bioremediation of age-related diseases.
Mathieu JM, Schloendorn J, Rittmann BE, Alvarez PJ. Mathieu JM, et al. Microb Cell Fact. 2009 Apr 9;8:21. doi: 10.1186/1475-2859-8-21. Microb Cell Fact. 2009. PMID: 19358742 Free PMC article.
Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation, and Down-Regulation of Mannose-6-Phosphate Receptors Cause Low Accessibility to Enzyme Replacement Therapy.
Frustaci A, Verardo R, Magnocavallo M, Frustaci E, Russo MA, Chimenti C. Frustaci A, et al. J Am Heart Assoc. 2025 Feb 18;14(4):e036815. doi: 10.1161/JAHA.124.036815. Epub 2025 Feb 8. J Am Heart Assoc. 2025. PMID: 39921501 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- Genetic Alliance